ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
횡문근육종 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 궤양 네트워크의 확대, 집학적 치료 접근에 기인하고 있습니다. 예측 기간의 주요 동향으로는 면역요법의 진보, 조기 발견을 위한 리퀴드 바이옵시, 약물 스크리닝을 위한 오가노이드, 방사선 치료 기술의 강화, 재생 의료 등이 있습니다.
종양학 연구와 의료 투자 증가는 횡문근육종 시장의 성장을 가속할 것으로 예측됩니다. 이러한 투자 증가는 세계 암 이환율 증가, 정밀의료의 진보, 혁신적인 치료법에 대한 수요, 임상 검사의 확대, 정부와 민간 자금 제공 이니셔티브에 의해 초래되고 있습니다. 이러한 투자는 조기 진단을 개선하고, 표적 치료 및 면역 요법과 같은 치료 옵션을 강화하며, 더 효과적인 약물에 대한 임상 시험 자금을 지원하고, 소아암 치료 인프라를 개선하며, 질병의 생물학적 특성과 진행 상황을 더 잘 이해할 수 있는 연구를 지원함으로써 횡문근육종 치료를 발전시키는 데 도움이 됩니다. 2024년 5월 인도에 본사를 둔 분석 회사인 IQVIA는 2023년 세계의 암치료에 대한 지출이 2,230억 달러에 이르렀고, 2022년 보다 250억 달러 증가한 수치라고 보고했습니다.
의료시설의 개선은 횡문근육종 시장의 성장을 가속할 것으로 예측됩니다. 이러한 시설의 충실은 의료 인프라에 대한 투자 증가, 환자 중심의 케어의 중시, 인구 증가, 고령화 등의 요인에 의해 추진되고 있습니다. 횡문근육종은 전문 진단 도구, 혁신적인 치료 프로토콜, 다학제적 치료 접근 방식을 필요로 하여 의료 시설의 발전을 주도하며, 궁극적으로 종양학 연구, 소아암 관리 및 표적 치료법 개발의 개선을 촉진합니다.
미국 의료 협회가 발표한 미국의 병원 수는 6,129개로 전년 6,093개 에서 0.591% 증가했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 횡문근육종 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 횡문근육종 시장 : 성장률 분석
세계의 횡문근육종 시장 실적 : 규모와 성장, 2019-2024년
세계의 횡문근육종 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 횡문근육종 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 횡문근육종 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
태아성 횡문근육종
치조골 횡문근육종
기타
세계의 횡문근육종 시장 : 치료별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
수술
방사선치료
화학요법
줄기세포요법
세계의 횡문근육종 시장 : 진단별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
화상 검사
X선
컴퓨터 단층 촬영 스캔
자기 공명 화상 스캔
양전자 방출 단층 촬영 스캔
뼈 스캔
생검
바늘 생검
외과적 생검
세계의 횡문근육종 시장 : 태아성 횡문근육종별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
보트릴로이드 횡문근육종
스핀들 세포 횡문근육종
세계의 횡문근육종 시장 : 폐포 횡문근육종(ARMS)의별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
융합 양성 ARMS
융합 음성 ARMS
세계의 횡문근육종 시장: 횡문근육종 다른 유형의별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
다형성 횡문근육종
혼합형 횡문근육종
경화성 횡문근육종
제7장 지역별/국가별 분석
세계의 횡문근육종 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 횡문근육종 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
횡문근육종 시장 :경쟁 구도
횡문근육종 시장 : 기업 프로파일
Pfizer Inc.
Merck & Co Inc.
Bristol-Myers Squibb Company
Thermo Fisher Scientific Inc.
AstraZeneca PLC
제31장 기타 주요 기업 및 혁신 기업
Novartis AG
Eli Lilly and Company
Gilead Sciences Inc.
GE HealthCare Technologies Inc.
Eisai Co Ltd.
Ipsen SA
Elekta AB
Acrivon Therapeutics Inc.
Larvol Inc.
Oasmia Pharmaceutical AB
Immix Biopharma Inc.
Cellectar Biosciences Inc.
Lantern Pharma Inc.
ApconiX Ltd.
Oncoheroes Biosciences Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
횡문근육종 시장, 2029년 : 새로운 기회를 제공하는 국가
횡문근육종 시장, 2029년 : 새로운 기회를 제공하는 부문
횡문근육종 시장, 2029년 : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Rhabdomyosarcoma refers to a type of cancer that arises from muscle tissue, primarily affecting children and young adults. Rhabdomyosarcoma is useful to identify and treat early, as early detection improves the chances of successful treatment and survival.
The main types of rhabdomyosarcoma are embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, and other types. Embryonal rhabdomyosarcoma (ERMS) is a common type of rhabdomyosarcoma that typically affects younger children and occurs in soft tissues such as muscles. The various treatments, include surgery, radiation therapy, chemotherapy, and stem cell therapy, and various diagnoses such as imaging tests, X-rays, computed tomography scans, magnetic resonance imaging scans, positron emission tomography scans, bone scans, biopsies, needle biopsies, and surgical biopsies.
The rhabdomyosarcoma research report is one of a series of new reports from The Business Research Company that provide rhabdomyosarcoma market statistics, including rhabdomyosarcoma industry global market size, regional shares, competitors with a rhabdomyosarcoma market share, detailed rhabdomyosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the rhabdomyosarcoma industry. This rhabdomyosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The rhabdomyosarcoma market size has grown rapidly in recent years. It will grow from $1.23 billion in 2024 to $1.43 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth during the historic period can be attributed to factors such as increased funding for cancer research, the availability of targeted therapies, advancements in surgical techniques and approaches, growth in pediatric oncology programs, and improvements in healthcare policies.
The rhabdomyosarcoma market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2029 at a compound annual growth rate (CAGR) of 16.1%. The growth during the forecast period can be attributed to enhanced understanding of cancer biology, improvement in prognostic tools, growing focus on early detection and prevention, expansion of global oncology networks, and multi-disciplinary treatment approaches. Major trends in the forecast period include advancements in immunotherapy, liquid biopsy for early detection, organoids for drug screening, enhanced radiotherapy techniques and regenerative medicine.
The rising investments in oncology research and medicine are expected to drive the growth of the rhabdomyosarcoma market. These investments refer to the financial contributions made by governments, pharmaceutical companies, research institutions, and private investors aimed at advancing the understanding, prevention, diagnosis, and treatment of cancer. The increasing investments are driven by the growing global cancer burden, advancements in precision medicine, the demand for innovative therapies, the expansion of clinical trials, and government and private funding initiatives. These investments help advance rhabdomyosarcoma treatments by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, improving pediatric cancer care infrastructure, and supporting research to better understand the disease's biology and progression. For example, in May 2024, IQVIA, an India-based analytics company, reported that global spending on cancer medicines reached $223 billion in 2023, marking a $25 billion increase from 2022. This spending is expected to rise to $409 billion by 2028, further driving growth in the rhabdomyosarcoma market.
Improvements in healthcare facilities are also expected to drive the growth of the rhabdomyosarcoma market. Healthcare facilities, such as hospitals, clinics, and diagnostic centers, offer essential medical care and support to patients. The enhancement of these facilities is driven by factors such as increased investment in healthcare infrastructure, a focus on patient-centered care, population growth, and aging. Rhabdomyosarcoma drives advancements in healthcare facilities by necessitating specialized diagnostic tools, innovative treatment protocols, and multidisciplinary care approaches, which ultimately foster improvements in oncology research, pediatric cancer management, and the development of targeted therapies. For example, in May 2023, the American Health Care Association reported that the United States had 6,129 hospitals, marking a 0.591% increase from the previous year, when there were 6,093 hospitals. This growth in healthcare facilities contributes to the expansion of the rhabdomyosarcoma market.
Regulatory approvals with rare pediatric disease designation (RPDD) are also enhancing the market presence. RPDD is a special status granted by regulatory agencies to encourage the development of treatments for serious, life-threatening rare diseases affecting children. For instance, in January 2022, Immix Biopharma, Inc., a US-based biotech company, received RPDD from the FDA for its drug IMX-110, designed to treat rhabdomyosarcoma in children. IMX-110 is the first clinical-stage product in the SMARxT Tissue-Specific Platform. It contains a poly-kinase inhibitor and apoptosis inducer that targets the tumor microenvironment. This drug works by accumulating at therapeutic sites more effectively than conventional drugs, attacking cancer cells, cancer-associated fibroblasts, and tumor-associated macrophages, which ultimately leads to tumor apoptosis. The RPDD approval helps expand the market presence for this treatment and solidifies its position in treating rhabdomyosarcoma.
Major players in the rhabdomyosarcoma market are Pfizer Inc., Merck & Co Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., GE HealthCare Technologies Inc., Eisai Co Ltd., Ipsen S.A., Elekta AB, Acrivon Therapeutics Inc., Larvol Inc., Oasmia Pharmaceutical AB, Immix Biopharma Inc., Cellectar Biosciences Inc., Lantern Pharma Inc., ApconiX Ltd., Oncoheroes Biosciences Inc.
North America was the largest region in the rhabdomyosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rhabdomyosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Rhabdomyosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rhabdomyosarcoma market consists of revenues earned by entities by providing services such as genetic testing, pain management, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rhabdomyosarcoma market also includes sales of chemotherapy agents, and combination regimes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Rhabdomyosarcoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on rhabdomyosarcoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for rhabdomyosarcoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rhabdomyosarcoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Embryonal Rhabdomyosarcoma; Alveolar Rhabdomyosarcoma; Other Types
2) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Stem Cell Therapy
3) By Diagnosis: Imaging Tests; X-Ray; Computed Tomography Scan; Magnetic Resonance Imaging Scan; Positron Emission Tomography Scan; Bone Scan; Biopsy; Needle Biopsy; Surgical Biopsy
Subsegments:
1) By Embryonal Rhabdomyosarcoma: Botryoid Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Rhabdomyosarcoma Market Characteristics
3. Rhabdomyosarcoma Market Trends And Strategies
4. Rhabdomyosarcoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Rhabdomyosarcoma Growth Analysis And Strategic Analysis Framework
5.1. Global Rhabdomyosarcoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Rhabdomyosarcoma Market Growth Rate Analysis
5.4. Global Rhabdomyosarcoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Rhabdomyosarcoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Rhabdomyosarcoma Total Addressable Market (TAM)
6. Rhabdomyosarcoma Market Segmentation
6.1. Global Rhabdomyosarcoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Embryonal Rhabdomyosarcoma
Alveolar Rhabdomyosarcoma
Other Types
6.2. Global Rhabdomyosarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Radiation Therapy
Chemotherapy
Stem Cell Therapy
6.3. Global Rhabdomyosarcoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imaging Tests
X-Ray
Computed Tomography Scan
Magnetic Resonance Imaging Scan
Positron Emission Tomography Scan
Bone Scan
Biopsy
Needle Biopsy
Surgical Biopsy
6.4. Global Rhabdomyosarcoma Market, Sub-Segmentation Of Embryonal Rhabdomyosarcoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Botryoid Rhabdomyosarcoma
Spindle Cell Rhabdomyosarcoma
6.5. Global Rhabdomyosarcoma Market, Sub-Segmentation Of Alveolar Rhabdomyosarcoma (ARMS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fusion-Positive ARMS
Fusion-Negative ARMS
6.6. Global Rhabdomyosarcoma Market, Sub-Segmentation Of Other Types of Rhabdomyosarcoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pleomorphic Rhabdomyosarcoma
Mixed-Type Rhabdomyosarcoma
Sclerosing Rhabdomyosarcoma
7. Rhabdomyosarcoma Market Regional And Country Analysis
7.1. Global Rhabdomyosarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Rhabdomyosarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
